Company Overview and News

0
Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance

2018-07-16 globenewswire
JERUSALEM and BOCA RATON, Fla., July 16, 2018 (GLOBE NEWSWIRE) -- Hollywood Media Corp. (OTC Pink:HOLL) (HMC) today announced the strategic transformation of the Company, its management and Board through an initial $2 million investment in Jerusalem, Israel-based NewStem Ltd. and a refocusing of HMC on the substantial commercial potential of NewStem’s novel diagnostic technology which can predict patients’ resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.
TATT AMBK KEWL HOLL ACFN PTX ADMA

6
ADMA / ADMA Biologics Inc null (Current Report)

2018-07-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

5
ADMA / ADMA Biologics Inc null

2018-06-30 sec.gov
ADMA Biologics, Inc. 465 State Route 17 Ramsey, New Jersey 07446 May 29, 2018
ADMA

8
ADMA / ADMA Biologics Inc null (Current Report)

2018-06-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

5
ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes

2018-06-25 globenewswire
RAMSEY, N.J. and BOCA RATON, Fla., June 25, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a vertically integrated commercial biopharmaceutical company that manufactures, markets and develops specialty plasma-based biologics for the prevention and treatment of certain infectious diseases, today announced that is has been added to the Russell 3000® Index and its subcomponent, the Russell 2000®Index.
ADMA

9
ADMA / ADMA Biologics Inc null (Current Report)

2018-06-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ADMA

15
ADMA / ADMA Biologics Inc null (Current Report)

2018-06-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
ADMA

10
ADMA Biologics: The Right Way To Fix Manufacturing

2018-06-14 seekingalpha
ADMA is in the third inning of a corporate turn-around. A manufacturing-related Warning Letter is preventing ADMA from reintroducing Bivigam to the market ($60m Revs/yr) and getting FDA approval for RI-002 (could be a $200m+/yr). While ADMA management has stated that their facility is inspection-ready, there has been a lot of uncertainty about the timing of the required FDA re-inspection and about the success of ADMA's efforts to fix the manufacturing issues.
ADMA

6
ADMA Biologics Announces Closing of $40M Public Offering

2018-06-12 globenewswire
RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share. The gross proceeds from the offering are approximately $40.0 million, before deducting underwriters’ discounts and commissions and other offering expenses payable by the Company.
ADMA

5
ADMA / ADMA Biologics Inc null (Current Report)

2018-06-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F
ADMA

182
Your Daily Pharma Scoop: Secondaries Review June 4-11

2018-06-12 seekingalpha
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis.
ZYME OPTN DCPH MDGL KSHB BTX TROV CATB VKTX COOL BICX MEIP EXAS VKTXW TPIV PAVM MRTX BCLI ADMA

8
ADMA / ADMA Biologics Inc / Broadfin Capital, LLC - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ADMA

7
ADMA / ADMA Biologics Inc / Broadfin Capital, LLC - null (Passive Investment)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
ADMA

9
ADMA / ADMA Biologics Inc null (Prospectus)

2018-06-08 sec.gov
Filed Pursuant to Rule 424(b)(5) Registration No. 333-225048
ADMA

5
ADMA / ADMA Biologics Inc null (Current Report)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F
ADMA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ADMA / ADMA Biologics Inc on message board site Silicon Investor.

ADMA - http://www.admabiologics.com/
CUSIP: 000899104